Hexarelin (Examorelin)

Published · Researched 2026-09-21

Research file — dated 2026-09-20. Research documentation only; not medical advice.

Overview — maker/originator, what it is, current 2026 status

Hexarelin, INN examorelin (developmental codes EP-23905, MF-6003), is a synthetic hexapeptide ghrelin-receptor (GHSR) agonist developed by Mediolanum Farmaceutici and derived from GHRP-6. It is described in the literature as the most potent of the GHRP family. It reached phase II clinical trials for growth hormone deficiency and congestive heart failure but did not complete development and was never marketed — it exists in 2026 solely as a research chemical. Despite never being a drug, it is one of the most heavily marketed peptides in social content. WADA-prohibited at all times (S2.2.4, listed as "examorelin (hexarelin)").

Sources: https://en.wikipedia.org/wiki/Examorelin (accessed 2026-09-20); https://www.drugs.com/wada/s2-peptide-hormones-growth-factors-and-related-substances.html

Social standing — platform pulse

  • Instagram: The single most-promoted GHRP in 2026 creator content. HNR Labs' Aug 2026 reel brands it "one of the strongest GH pulses" / "a potent growth hormone secretagogue" over a CGI heart (https://www.facebook.com/reel/4666947126862489/; mirrored on IG). Peptide Manager Pro's Aug 2026 carousel calls it the strongest GHRP ever developed with "2-3x stronger" GH release than GHRP-2, citing dual GHS-R1a + CD36 action and a tolerance-graph showing ~45% GH-response drop over 16 weeks. GenDarwin Research (Aug 2026) runs a 10-slide brief touting "strongest GH pulse" plus cardioprotective claims via CD36. Titan Medical Center runs Hexarelin therapy promos. IFBB pro Steve Kuclo lists hexarelin among peptides he'd "research" for recovery (Mar 2026). Paul Simpson's Feb 2026 tier-list video places hexarelin in C tier (muscle 8.5/10, fat loss 7.5/10, recovery 8/10, side effects 5.5/10). Restore Clinic's "Ipamorelin vs Hexarelin" explainer frames hexarelin as the non-selective heavy hitter that raises prolactin and cortisol.
  • Facebook Groups: Recommended in GH threads as the strongest GHRP to pair with sermorelin ("Hexarelin as the strongest option due to pituitary saturation limits" — FB group comment thread, Dec 2025).
  • Threads: Peptara Labs' Sept 19, 2026 post markets Hexarelin as "beats a hormone at its own job," with brand-authored comments noting hexarelin outperforms GHRH in healthy men — caveated by the brand itself that moving GH on a blood test is not proven benefit (https://www.threads.com/@peptaralabs_io/post/DdemptGj35c).
  • Group consensus: Acknowledged as the most potent GH-releasing peptide, but with the heaviest side-effect and desensitization baggage — respected, feared, and used in short bursts rather than long runs.
  • Viral moments: HNR Labs' Aug 2026 "strongest GH pulses" reel and the Peptide Manager Pro carousel (with the 16-week tolerance graph) are the most-circulated assets.
  • Main praise: Strongest GH pulse of any GHRP; cardioprotective/CD36 research angle (vendor-cited, not established); potent appetite for bulking contexts.
  • Main complaints: Desensitization — community and literature report ~45–75% GH-response loss over weeks–months of continuous use; raises prolactin and cortisol; ChemCenterBio's Sept 2026 reel warns early GHRP-2/6 trials caused "internal systemic chaos" in animals (creator claim, UNVERIFIED as stated) while positioning ipamorelin as cleaner.
  • Quotes: HNR Labs: "one of the strongest GH pulses" (Aug 2026 reel).

Social validation — Tier 1

Tier 1 — FB Groups (stacking threads), Instagram (dense owner/educator content: HNR Labs, Restore Clinic, GenDarwin, Peptide Manager Pro, Titan Medical), Threads (Peptara Labs Sept 2026).

Named sources:

Key specs table

Spec Detail
Class Synthetic hexapeptide GHRP; derived from GHRP-6
Sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 (verified via Wikipedia, 2026-09-20)
Mechanism Ghrelin-receptor (GHSR-1a) agonist; reported CD36 binding in cardiac tissue — UNVERIFIED clinical relevance
Half-life ~55 minutes (verified via Wikipedia, 2026-09-20)
Route IV, subcutaneous, intranasal, oral studied; community uses subcutaneous
Community-reported dosing Typically 100–200 mcg per pulse, cycled short (community ranges; exact consensus UNVERIFIED); often paired with a GHRH
Molecular weight / CAS 887.06 g/mol; CAS 140703-51-1 (verified via Wikipedia, 2026-09-20)
Desensitization Partial, reversible tolerance: 50–75% decrease in GH-releasing efficacy over weeks–months of long-term administration (Rahim et al. 1998; Ghigo 1999, via Wikipedia)

Pricing

  • Approved-drug price: Not applicable — never marketed as a drug.
  • Research-chem price: Gray-market vial prices not collected 2026-09-20 — UNVERIFIED.
  • Compounded/clinic price: Not applicable — no legitimate compounded-therapy channel (note: some wellness clinics market "hexarelin therapy," e.g., Titan Medical promos, but this is not a recognized compounded product).
  • Marketplace range: No listings observed 2026-09-20.

What's included / what's needed

  • Research-chem listing: one lyophilized vial (common sizes 2 mg or 5 mg seen in product shots — offerings UNVERIFIED).
  • What's needed alongside (factual, not instructions): bacteriostatic water for reconstitution, insulin syringes.

Support reality

  • Pharma support: None — never a marketed drug; no manufacturer patient program.
  • Research-chem COA practices: Vendors typically claim ≥99% purity with third-party COAs; quality unverified here.
  • Clinic support: None legitimate; clinic "hexarelin therapy" marketing exists but is not a regulated product.

Regulatory & safety status

Plain statement: Research chemical not for human use. Never approved by FDA or EMA; clinical development (phase II, GHD and congestive heart failure) was discontinued. WADA-prohibited at all times (S2.2.4, "examorelin (hexarelin)"). Safety signals from literature: dose-dependent GH increase plus dose-dependent prolactin, ACTH, and cortisol elevation (Arvat 1997; Massoud 1995); documented partial, reversible tolerance with chronic use (50–75% efficacy loss over weeks–months); no effect on glucose, LH, FSH, TSH in humans (Imbimbo 1994, via Wikipedia). Conflicting reports on IGF-1 elevation — some studies find none.

Community verdict

Hexarelin carries the "most potent GHRP" crown in community lore and in the vendor content that profits from it, but the consensus is that the crown is expensive: documented desensitization, cortisol/prolactin elevation, and short-cycle-only use keep it as a niche heavy hitter rather than a daily driver. Much of the loudest promotion is vendor-authored.

Image log

Open questions / UNVERIFIED

  • Exact current gray-market price per vial.
  • Vendor potency claims ("10x GHRP-6," "2–3x GHRP-2," "peak GH 38–44 ng/mL") — from vendor carousels, not verified.
  • Cardioprotective/CD36 claims as a human benefit — preclinical research angle used in marketing; no clinical outcome data verified.
  • ChemCenterBio's claim of "hearts and livers swelling to nearly twice normal size" in early GHRP trials — creator claim, not verified.
  • Community consensus dosing ranges (100–200 mcg) — widely repeated, not traced to a single source.

Not medical advice. This file is research documentation only; nothing here is a recommendation to use any compound.

Hexarelin (Examorelin) — box view
box view Original vendor page URL not recorded in research dossier
Hexarelin (Examorelin) — detail view
detail view Original vendor page URL not recorded in research dossier
Hexarelin (Examorelin) — hero view
hero view Original vendor page URL not recorded in research dossier
Hexarelin (Examorelin) — side view
side view Original vendor page URL not recorded in research dossier

Sources